Log in

Relevant bibliographies by topics / PN 35.5 UL 2008 / Journal articles

To see the other types of publications on this topic, follow the link: PN 35.5 UL 2008.

Journal articles on the topic 'PN 35.5 UL 2008'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 21 journal articles for your research on the topic 'PN 35.5 UL 2008.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Seetharam, Mahesh, Olga K. Weinberg, Li Ren, et al. "AML Patients with Monosomal Karyotype Are Characterized by Absence of NPM1 and FLT3 Mutations and Worse Clinical Outcome." Blood 114, no. 22 (2009): 2638. http://dx.doi.org/10.1182/blood.v114.22.2638.2638.

Full text

Abstract:

Abstract Abstract 2638 Poster Board II-614 Background: The importance of cytogenetics in prognosis of AML is now widely recognized and accepted in clinical practice. A recent study found that autosomal chromosomal monosomy predicted for an adverse outcome. The goal of this study is to characterize patients with monosomal karyotype by mutation status and clinical features. Methods: One-hundred forty consecutive AML patients diagnosed at Stanford University Hospital between 2005 and 2008 with adequate material for mutation analysis were studied. Cases were classified using the 2008 WHO criteria.

APA, Harvard, Vancouver, ISO, and other styles

2

Richardson, Paul G., Jordi Bruna, Anthony A. Amato, et al. "Bortezomib-Associated Peripheral Neuropathy: Relationship Between Clinical Neurophysiologic Evidence in Previously Untreated Multiple Myeloma Patients and Preclinical Characterization in a Mouse Model." Blood 114, no. 22 (2009): 3860. http://dx.doi.org/10.1182/blood.v114.22.3860.3860.

Full text

Abstract:

Abstract Abstract 3860 Poster Board III-796 Bortezomib (Velcade®) therapy for multiple myeloma (MM) results in high overall and complete response rates, but can also lead to peripheral neuropathy (PN). Bortezomib-associated PN has been shown to be a cumulative, dose-related, primarily sensory neuropathy that is reversible to baseline in the majority of cases (Richardson et al, Br J Haematol 2009). Further research is needed to determine the mechanisms by which PN arises and to determine potential neuroprotective strategies. A preclinical model that reflects the neurophysiologic changes seen in

APA, Harvard, Vancouver, ISO, and other styles

3

Vera, L., R. Reategui, B. Beltran, et al. "The clinicopathological spectrum of HIV-associated lymphoma: Eleven-year-experience in a general hospital in Peru." Journal of Clinical Oncology 27, no. 15_suppl (2009): e19561-e19561. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e19561.

Full text

Abstract:

e19561 Background: The clinicopathological spectrum of HIV-associated lymphomas in developing countries has not been clearly defined. Thus, this study is aimed to describe these features in cases from a Peruvian population. Methods: This is a retrospective review of the clinical records of patients with diagnosis of HIV in our institution from March 1997 to March 2008. We reviewed 2502 clinical records. The statistical method was descriptive and survival was calculated using the Kaplan-Meier method. Results: Forty-eight patients with HIV-associated lymphoma were identified. Male:female ratio w

APA, Harvard, Vancouver, ISO, and other styles

4

Bartsch, Fabian, Lisa-Katharina Heuft, Janine Baumgart, et al. "Influence of Lymphangio (L), Vascular (V), and Perineural (Pn) Invasion on Recurrence and Survival of Resected Intrahepatic Cholangiocarcinoma." Journal of Clinical Medicine 10, no. 11 (2021): 2426. http://dx.doi.org/10.3390/jcm10112426.

Full text

Abstract:

(1) Background: Intrahepatic cholangiocarcinoma (ICC) is a rare malignancy. Besides tumor, nodal, and metastatic status, the UICC TNM classification describes further parameters such as lymphangio- (L0/L1), vascular (V0/V1/V2), and perineural invasion (Pn0/Pn1). The aim of this study was to analyze the influence of these parameters on recurrence and survival. (2) Methods: All surgical explorations for patients with ICC between January 2008 and June 2018 were collected and further analyzed in our institutional database. Statistical analyses focused on perineural, lymphangio-, and vascular invas

APA, Harvard, Vancouver, ISO, and other styles

5

Cai, Yuli, Chao Liu, Ye Guo, et al. "Analysis of 48 Cases Pediatric Chronic Myeloid Leukemia from China: Results from a Single Institute in China." Blood 134, Supplement_1 (2019): 5911. http://dx.doi.org/10.1182/blood-2019-125565.

Full text

Abstract:

Objective: Chronic myeloid leukemia (CML) is a rare disease among children. It comprises 3% of childhood leukemias. CML in children is different from CML in adult. Here we analyzed the clinical features and prognosis of pediatric CML in a single institute from China. Methods: A retrospective study was performed by reviewing clinical records of pediatric CML from 2002 to 2019. Results: A total of 48 pediatric CML cases were included in the study, with 35 males and 13 females (M: F=2.7:1). Four cases were diagnosed during 2002~2007, 12 cases during 2008~2013 and 32 cases during 2014~2019. Two (4

APA, Harvard, Vancouver, ISO, and other styles

6

Beltran, Brady E., Erick Cotacallapa, and Jorge J. Castillo. "Survival and Clinicopathological Characteristics of EBV-Positive Diffuse Large B-Cell Lymphoma." Blood 120, no. 21 (2012): 1588. http://dx.doi.org/10.1182/blood.v120.21.1588.1588.

Full text

Abstract:

Abstract Abstract 1588 Background: EBV-positive diffuse large B-cell lymphoma (EBV+ DLBCL) of the elderly is a provisional entity included in the 2008 WHO Classification of Lymphomas. Diagnostic criteria include age >50 years, DLBCL morphology and EBV expression in lymphomatous cells. However, these criteria are evolving as several patients are <50 years and a specific cut-off for the percentage of EBV expression has not been defined. The goal of this retrospective study is to evaluate clinical and pathological characteristics of EBV+ DLBCL from Peruvian patients. Methods: Between Januar

APA, Harvard, Vancouver, ISO, and other styles

7

Chalasani, Venu, Wassim Kassouf, Joseph L. Chin, et al. "Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience." Canadian Urological Association Journal 5, no. 2 (2013): 83. http://dx.doi.org/10.5489/cuaj.587.

Full text

Abstract:

Background: Radical cystectomy may provide optimal survivaloutcomes in the management of clinical T1 bladder cancer. Wepresent our data from a large, multi-institutional, contemporaryCanadian series of patients who underwent radical cystectomy forclinical T1 bladder cancer in a single-payer health care system.Methods: We collected a pooled database of 2287 patients whounderwent radical cystectomy between 1993 and 2008 in 8 differentcentres across Canada; 306 of these patients had clinical T1bladder cancer. Survival data were analyzed using Kaplan-Meiermethod and Cox regression analysis.Results

APA, Harvard, Vancouver, ISO, and other styles

8

Rosenthal, Allison C., Amylou Constance Dueck, Katherine Gano, et al. "A Phase II Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone (R-CyBor-D) in Relapsed Low Grade and Mantle Cell Lymphoma." Blood 124, no. 21 (2014): 4410. http://dx.doi.org/10.1182/blood.v124.21.4410.4410.

Full text

Abstract:

Abstract Introduction Non-Hodgkin lymphoma responds to single agents such as cyclophosphamide, combination therapy such as CVP and immunotherapy with monoclonal antibodies such as rituximab. There is no consensus on the optimal treatment for relapsed low grade or mantle cell lymphoma. Based on the success and tolerability of combining alkylating agents with proteasome inhibitors in multiple myeloma, a phase II clinical trial of rituximab, cyclophosphamide, bortezomib, and dexamethasone (R-CyBor-D) was designed to explore the efficacy and safety of this combination in relapsed low grade and man

APA, Harvard, Vancouver, ISO, and other styles

9

Beltran, Brady E., Julio C. Chavez, Eduardo M. Sotomayor, and Jorge J. Castillo. "Lymphopenia Is an Adverse Prognostic Factor in EBV-Positive Diffuse Large B-Cell Lymphoma." Blood 124, no. 21 (2014): 5408. http://dx.doi.org/10.1182/blood.v124.21.5408.5408.

Full text

Abstract:

Abstract Background: EBV-positive diffuse large B-cell lymphoma (EBV+ DLBCL) of the elderly is a provisional entity included in the 2008 WHO Classification of Lymphomas. Diagnostic criteria include age >50 years, DLBCL morphology and EBV expression in lymphomatous cells. However, these criteria are evolving as several patients younger than 50 years of age without immunodeficiency have been diagnosed. Also, a specific cut-off for the percentage of EBV expression has not been defined. Lymphopenia, monocytosis, neutrophil-to-lymphocyte ratio (NLR) and the lymphocyte-to-monocyte ratio (LMR) hav

APA, Harvard, Vancouver, ISO, and other styles

10

Yasenchak, Christopher A., Rodolfo Eduardo Bordoni, Dipti Patel-Donnelly, et al. "Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients." Journal of Clinical Oncology 38, no. 15_suppl (2020): 8032. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.8032.

Full text

Abstract:

8032 Background: Older patients with classical Hodgkin lymphoma (cHL) have poor outcomes relative to younger patients, often due to comorbidities and toxicities related to standard first-line (1L) chemotherapy (5-yr PFS: 30%–45% vs 75%–80%) (Evens 2008; Proctor 2009). Brentuximab vedotin (BV, ADCETRIS®), a CD30-directed antibody-drug conjugate, has robust activity in patients refractory to several lines of chemotherapy. Methods: This phase 2, open-label study, SGN35-015 (NCT01716806), evaluated efficacy and tolerability of BV alone or combined with single-agents in treatment-naive cHL patients

APA, Harvard, Vancouver, ISO, and other styles

11

Kim, Yeo-Kyeoung, Se Ryeon Lee, Yong Park, et al. "Efficacy Of Ruxolitinib In Korean Myelofibrosis Patients and Cases Complicated TB Lymphadenitis During The Treatment." Blood 122, no. 21 (2013): 1596. http://dx.doi.org/10.1182/blood.v122.21.1596.1596.

Full text

Abstract:

Abstract Introduction Ruxolitinib is a selective JAK 1/2 inhibitor, which shows an excellent treatment outcome in myelofibrosis (MF) patients. Main side effect of JAK 1/2 inhibitors is an increased risk of infection. JAK1/2 inhibition may interfere with the differentiation of interferon-γ (IFN-γ) producing Th1 cells and IFN-γ is a key cytokine involved in protective immunity against Mycobacterium tuberculosis(TB). During COMPORT-II trial, a case of disseminated TB with ruxolitinib was reported. Here, we analyze the efficacy and safety of ruxolitinib in Korean MF patients and report cases of TB

APA, Harvard, Vancouver, ISO, and other styles

12

Fowler, Nathan, Brad S. Kahl, Peter Rosen, et al. "Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study." Blood 114, no. 22 (2009): 933. http://dx.doi.org/10.1182/blood.v114.22.933.933.

Full text

Abstract:

Abstract Abstract 933 Follicular lymphoma (FL) is an incurable, indolent B-cell non-Hodgkin lymphoma. Although survival has improved with the introduction of rituximab (Rituxan®, R), relapse is inevitable and new therapies are needed. Bortezomib (Velcade®, V) plus rituximab is active in relapsed or refractory (rel/ref) FL (de Vos et al, ASH 2006). Bendamustine (Treanda®, B) plus R has also shown activity in rel/ref FL (Robinson et al, J Clin Oncol 2008), and V has been safely combined with B in patients (pts) with advanced multiple myeloma (Fenk et al, Leuk Lymph 2007). The single-arm, multice

APA, Harvard, Vancouver, ISO, and other styles

13

Zemanova, Milada, Zdenka Pechacova, Tomas Harustiak, Pavel Fencl, Pavel Vitek, and Lubos B. Petruzelka. "Perioperative management of patients with distal esophagus and gastroesophageal junction tumors: Three years of results." Journal of Clinical Oncology 30, no. 15_suppl (2012): e14631-e14631. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e14631.

Full text

Abstract:

e14631 Background: In patients with operable gastroesophageal adenocarcinoma, a perioperative regimen ECF significantly improved survival (MAGIC trial - Cunnigham 2006) and has been accepted as standard treatment option. In our study we present experience with modified MAGIC protocol in patients with lower esophagus or GE junction tumors. Methods: 67 patients (pts) (60 men, 7 women), median age 59 years (37-74), with resectable adenocarcinoma in lower esophagus or gastroesophageal junction were included in period 01 Mar 2008 – 15 Jun 2010. Fifty one (76%) pts had clinical stage nodal positive.

APA, Harvard, Vancouver, ISO, and other styles

14

Liu, Yang, Ali Tabarroki, Valeria Visconte, et al. "A Prognostic Scoring System for Unclassifiable MDS and MDS/MPN." Blood 120, no. 21 (2012): 1701. http://dx.doi.org/10.1182/blood.v120.21.1701.1701.

Full text

Abstract:

Abstract Abstract 1701 Patients with features of MDS and MDS/MPN who do not fulfill diagnostic criteria for a specific subtype of MDS and MDS/MPN are categorized by the WHO 2008 diagnostic criteria as MDS-U and MDS/MPN-U. MDS includes RCUD, RCMD, RARS, RAEB-1, RAEB-2, MDS-U and 5q- syndrome while MDS/MPN includes CMML, JMML, atypical CML and MDS/MPN-U. The natural history of patients who belong to these disease subtypes are hetergeneous. Although included in currently accepted prognostic scoring schemes like the International Prognostic Scoring System (IPSS) in MDS, Revised IPSS, and MD Anders

APA, Harvard, Vancouver, ISO, and other styles

15

Fu, Chengcheng, Juan Wang, Xuefeng He, Ting Xu, Ri Zhang, and Wu Depei. "Refractory NK/T Cell Lymphoma Treated with Bortezomib+Chemotherapy and APBSCT." Blood 116, no. 21 (2010): 4602. http://dx.doi.org/10.1182/blood.v116.21.4602.4602.

Full text

Abstract:

Abstract Abstract 4602 Backgrouds: NK/T cell lymphoma is a rare disease, but usually shows a highly aggressive clinical course and its prognosis is poor due to the stumbling block in early diagnosis and effective management. Until present, there are no consensus treatments especially for recurrent patients. Bortezomib, and other new drugs are subject to active investigation, although only limited preliminary information is available. Here, 3 cases of refractory disseminated NK/T cell lymphoma were treated with Bortezomib plus high dose chemotherapy as salvage therapy. Patients and methods: Fro

APA, Harvard, Vancouver, ISO, and other styles

16

Takagi, Shinsuke, Kazuya Ishiwata, Masanori Tsuji, et al. "Voriconazole Is Safe and Effective as a Prophylactic Regimen of Invasive Fungal Infections for High Risk Patients after Reduced-Intensity Umbilical Cord Blood Transplantation." Blood 112, no. 11 (2008): 4355. http://dx.doi.org/10.1182/blood.v112.11.4355.4355.

Full text

Abstract:

Abstract Invasive fungal infections (IFI) are significant complications after allogeneic hematopoietic stem cell transplantation. We previously reported that 3-year cumulative incidence of IFI was 10.2 % and median onset of IFI was day 20 post reduced-intensity umbilical cord blood transplantation (RI-CBT) under the prophylaxis by fluconazole or micafungin (Biol Bone Marrow Transplant2007;13:771). In recent years, voriconazole (VOR) has been employed in IFI prophylactic regimens during bone marrow or peripheral blood stem cell transplantation in several clinical trials and reports, but the saf

APA, Harvard, Vancouver, ISO, and other styles

17

Schiffman, Schiffman D., Jonathan Downie, Bradley Demarest, et al. "Novel Use of Molecular Inversion Probes to Interrogate Formalin-Fixed Paraffin-Embedded (FFPE) Samples of Childhood Leukemia." Blood 114, no. 22 (2009): 1589. http://dx.doi.org/10.1182/blood.v114.22.1589.1589.

Full text

Abstract:

Abstract Abstract 1589 Poster Board I-615 Genome-wide, high-resolution analyses of copy number alterations (CNAs) now play an increasingly important role in identifying new genomic loci associated with leukemia biology and prognosis. The most powerful of these studies include large numbers of patients with associated clinical features and outcome data. Molecular Inversion Probes (MIPs) analyze genetic target sequences in parallel at the highest genomic resolution and can detect both gene copy number and allelic imbalance in clinical samples, and have been demonstrated to work on archived forma

APA, Harvard, Vancouver, ISO, and other styles

18

Noroozi, Nastaran, Donna E. Reece, Suzanne Trudel, et al. "“Longterm Survival (≥10 years) in Multiple Myeloma (MM) Is Associated with Longer Duration of Therapy and Improved Quality of Response to Novel agents”." Blood 114, no. 22 (2009): 2793. http://dx.doi.org/10.1182/blood.v114.22.2793.2793.

Full text

Abstract:

Abstract Abstract 2793 Poster Board II-769 Introduction: Over the past decade, survival of MM patients (pts) has improved significantly, with median survival currently estimated at 4-4.5 years (yrs). Much of this improvement can be attributed to the introduction of novel agents such as bortezomib and the immunomodulatory drugs in the late 1990's (Kumar et al, Blood 2008). Despite these therapeutic advances, long-term survivors of ≥10 yrs in MM are uncommon and account for <10% of pts. In this report, we identified 39 MM pts diagnosed over a 4 yr period (1994-1998) at our institution who hav

APA, Harvard, Vancouver, ISO, and other styles

19

Litvinov, Rustem I., Paul C. Billings, Craig N. Streu, John W. Weisel та Joel S. Bennett. "Time-Dependent Single-Molecule Interactions of the Platelet Integrin αIIbβ3 with Cyclic Arg-Gly-Asp and the Fibrin(ogen) γC-Dodecapeptide". Blood 116, № 21 (2010): 2103. http://dx.doi.org/10.1182/blood.v116.21.2103.2103.

Full text

Abstract:

Abstract Abstract 2103 Both fibrinogen and fibrin bind to the platelet integrin αIIbβ3 (GPIIb-IIIa). There are at least two motifs in human fibrin(ogen) that bind to αIIbβ3: HHLGGAKQAGDV located at position 400–411 at the C-terminus of the γ chain and RGD located at position 572–574 in the Aα (or α) chain. A second RGD motif located at position 95–97 in the Aα (or α) chain may also play a role in αIIbβ3-mediated platelet adhesion on fibrin(ogen). Recent crystal structures of αIIbβ3 containing either a γ chain peptide corresponding to residues 404–411 or linear RGD-containing peptide (Springer

APA, Harvard, Vancouver, ISO, and other styles

20

Yasenchak, Christopher A., Rodolfo Bordoni, Dipti Patel-Donnelly, et al. "Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients." Blood 136, Supplement 1 (2020): 18–19. http://dx.doi.org/10.1182/blood-2020-136583.

Full text

Abstract:

Introduction: Older patients with classical Hodgkin lymphoma (cHL) have poor outcomes relative to younger patients, often due to comorbidities and toxicities related to standard first-line (1L) chemotherapy (5-yr PFS: 30%-45% vs 75%-80%) (Evens 2008; Proctor 2009). Brentuximab vedotin (BV), a CD30-directed antibody-drug conjugate, has robust activity in patients refractory to several lines of chemotherapy. Methods: This phase 2, open-label study, SGN35-015 (NCT01716806), evaluated efficacy and tolerability of BV alone or combined with single-agents in treatment-naive cHL patients ≥60 yr. The f

APA, Harvard, Vancouver, ISO, and other styles

21

Ganzel, Chezi, Wang Xin Victoria, Adele K. Fielding, et al. "in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993." Blood 126, no. 23 (2015): 795. http://dx.doi.org/10.1182/blood.v126.23.795.795.

Full text

Abstract:

Abstract This study was coordinated by the ECOG-ACRIN Cancer Research Group (Robert L. Comis, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs) and the Medical Research Counsel, United Kingdom, and supported in part by Public Health Service Grants CA180820, CA180794, CA180790, CA189859, CA180853, CA180791, and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. Background: Late relapse

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!